ArticleScientific reports2016
T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 56 citations in OpenAlex.
- A Drug-Gated, Modular STAb-T Immunotherapy With External Control.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocol.PLoS computational biology · 2026Article
- Optimization of head and neck cancer peripheral blood mononuclear cell processing for robust downstream functional immune analysis.medRxiv : the preprint server for health sciences · 2026Article
- Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms.Journal for immunotherapy of cancer · 2026Review
- Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy.Molecular cancer · 2025Review
- Challenges in the preclinical design and assessment of CAR-T cells.Frontiers in immunology · 2025Review
- Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies.Frontiers in immunology · 2024Review
- Challenges and solutions for therapeutic TCR-based agents.Immunological reviews · 2023Review
- Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells.Gene therapy · 2023Article
- Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation.Haematologica · 2023Article
- Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.Blood · 2022Article
- Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.Journal for immunotherapy of cancer · 2022Article
- Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.Cancer immunology research · 2022Article
- Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.Oncoimmunology · 2022Article
- Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models.Frontiers in immunology · 2022Article
- Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.Oncoimmunology · 2022Article
- Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma.PloS one · 2022Article
- Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity.Science translational medicine · 2021Article
- Engineered mRNA and the Rise of Next-Generation Antibodies.Antibodies (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
T cells expressing chimeric antigen receptors (CARs) or the infusion of bispecific T-cell engagers (BITEs) have shown antitumor activity in humans for CD19-positive malignancies. While BITEs redirect the large reservoir of resident T cells to tumors, CAR T cells rely on significant in vivo expansion to exert antitumor activity. We have shown that it is feasible to modify T cells to secrete solid tumor antigen-specific BITEs, enabling T cells to redirect resident T cells to tumor cells. To adapt this approach to CD19-positive malignancies we now generated T cells expressing secretable, CD19-specific BITEs (CD19-ENG T cells). CD19-ENG T cells recognized tumor cells in an antigen-dependent manner as judged by cytokine production and tumor killing, and redirected bystander T cells to tumor cells. Infusion of CD19-ENG T cells resulted in regression of leukemia or lymphoma in xenograft models and a survival advantage in comparison to control mice. Genetically modified T cells expressing engager molecules may present a promising addition to current CD19-targeted immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.